GLP1R and type 2 diabetes mellitus: Previous studies have suggested that GLP-1R agonists can improve the risk of cardiovascular disease in diabetic patients, while in this study, there was no difference in the distribution of T2DM between the CHD group and the HC group, thus avoiding the bias caused by the difference in the distribution of diabetic patients between the two groups.